Joseph Polex-Wolf, Kristine Deibler, Wouter Frederik Johan Hogendorf, Sarah Bau, Tine Glendorf, Carsten Enggaard Stidsen, Christian Wenzel Tornøe, Dong Tiantang, Sofia Lundh, Charles Pyke, Abigail J. Tomlinson, Stace Kernodle, Irwin Jack Magrisso, Kilian W. Conde-Frieboes, Martin G. Myers, Lotte Bjerre Knudsen, Randy J. Seeley
{"title":"Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist","authors":"Joseph Polex-Wolf, Kristine Deibler, Wouter Frederik Johan Hogendorf, Sarah Bau, Tine Glendorf, Carsten Enggaard Stidsen, Christian Wenzel Tornøe, Dong Tiantang, Sofia Lundh, Charles Pyke, Abigail J. Tomlinson, Stace Kernodle, Irwin Jack Magrisso, Kilian W. Conde-Frieboes, Martin G. Myers, Lotte Bjerre Knudsen, Randy J. Seeley","doi":"10.1126/scitranslmed.adk4908","DOIUrl":null,"url":null,"abstract":"Glucagon-like peptide-1 (GLP-1) and leptin signal recent feeding and long-term energy stores, respectively, and play complementary roles in the modulation of energy balance. Previous work using single-cell techniques in mice revealed the existence of a population of leptin receptor ( <jats:italic>Lepr</jats:italic> )–containing dorsomedial hypothalamus (DMH) neurons marked by the expression of GLP-1 receptor ( <jats:italic>Glp1r</jats:italic> ; LepR <jats:sup>Glp1r</jats:sup> neurons) that play important roles in the control of feeding and body weight by leptin. Here, we demonstrate the existence of a population of LepR <jats:sup>Glp1r</jats:sup> neurons in the DMHs of nonhuman primates (NHPs), suggesting the potential translational relevance of these neurons. Consequently, we developed a GLP-1R/LepR dual agonist and demonstrated the physiological activity of both components in vivo using leptin-deficient and <jats:italic>Lepr-</jats:italic> deficient murine models. We further found roles for LepR <jats:sup>Glp1r</jats:sup> neurons in mediating the dual agonist’s efficacy on food intake and body weight loss. Ablating <jats:italic>Lepr</jats:italic> in <jats:italic>Glp1r</jats:italic> -expressing neurons (Lepr <jats:sup>Glp1r</jats:sup> KO mice) abrogated the suppression of food intake by the dual agonist. Furthermore, reactivation of <jats:italic>Glp1r</jats:italic> expression in <jats:italic>Lepr</jats:italic> neurons on an otherwise <jats:italic>Glp1r</jats:italic> -null background (Glp1r <jats:sup>Lepr</jats:sup> Re mice) was sufficient to permit the suppression of food intake and body weight by the dual agonist. Hence, LepR <jats:sup>Glp1r</jats:sup> neurons represent targets for a GLP-1R/LepR dual agonist that potently reduces food intake and body weight.","PeriodicalId":21580,"journal":{"name":"Science Translational Medicine","volume":"2666 1","pages":""},"PeriodicalIF":15.8000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1126/scitranslmed.adk4908","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Glucagon-like peptide-1 (GLP-1) and leptin signal recent feeding and long-term energy stores, respectively, and play complementary roles in the modulation of energy balance. Previous work using single-cell techniques in mice revealed the existence of a population of leptin receptor ( Lepr )–containing dorsomedial hypothalamus (DMH) neurons marked by the expression of GLP-1 receptor ( Glp1r ; LepR Glp1r neurons) that play important roles in the control of feeding and body weight by leptin. Here, we demonstrate the existence of a population of LepR Glp1r neurons in the DMHs of nonhuman primates (NHPs), suggesting the potential translational relevance of these neurons. Consequently, we developed a GLP-1R/LepR dual agonist and demonstrated the physiological activity of both components in vivo using leptin-deficient and Lepr- deficient murine models. We further found roles for LepR Glp1r neurons in mediating the dual agonist’s efficacy on food intake and body weight loss. Ablating Lepr in Glp1r -expressing neurons (Lepr Glp1r KO mice) abrogated the suppression of food intake by the dual agonist. Furthermore, reactivation of Glp1r expression in Lepr neurons on an otherwise Glp1r -null background (Glp1r Lepr Re mice) was sufficient to permit the suppression of food intake and body weight by the dual agonist. Hence, LepR Glp1r neurons represent targets for a GLP-1R/LepR dual agonist that potently reduces food intake and body weight.
期刊介绍:
Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research.
The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases.
The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine.
The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.